UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 31, 2016

 

 

 

GenVec, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(state or other jurisdiction of
incorporation)

         000-24469

       (Commission

        File Number)

23-2705690

(I.R.S. Employer

Identification No.)

     

 

910 Clopper Road

Suite 220N

Gaithersburg, Maryland

20878
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (240) 632-0740

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 

Section 7 – Regulation FD

 

Item 7.01. Regulation FD Disclosure.

 

On August 31, 2016, press reports disclosed that Novartis is planning to eliminate its internal unit dedicated to cell and gene therapy and redeploy most of the affected employees.  Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement between the two parties.  Novartis has informed GenVec that it remains engaged on the CGF166 program and that Novartis's internal changes are not expected or intended to reduce its support for the program.

 

 
 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GENVEC, INC.
     
     
    By:    /s/ Douglas J. Swirsky
        Douglas J. Swirsky
        President, Chief Executive Officer and Corporate
  Secretary

 

  

Dated: September 1, 2016